Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)
In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), ...
Oppenheimer Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.
PNC Financial Services Group Inc. Raises Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)
PNC Financial Services Group Inc. raised its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 22.9% during ...
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. So should ORIC Pharmaceuticals ...
Stifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)
Detailed price information for Black Diamond Therapeutics Inc (BDTX-Q) from The Globe and Mail including charting and trades.
TipRanks on MSN14d
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth
Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Oric ...
ETF Daily News21d
ORIC Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Monday
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) is expected to post its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect ORIC Pharmaceuticals to ...
manilatimes21d
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ...